A Board Member Bought Shares of Kronos Worldwide

Page 1 of 2

According to a filing with the SEC, Glenn Simmons, who serves on the Board of Directors at Kronos Worldwide, Inc. (NYSE:KRO) purchased 5,000 shares of the specialty chemicals company on January 19th at prices of about $19.20 per share. Simmons now owns over 48,000 shares of Kronos Worldwide, Inc. directly- so this purchase was a significant percentage increase in his holdings- and his spouse owns an additional 24,000 shares. Simmons was buying shares in November 2012 at prices around $13.30 per share; even though the stock is up 34% in the last three months, he apparently believes that it still has further to rise. See more of his insider trading activity and our history of insider purchases at Kronos. As of this writing, however, the stock price has increased further and is now at about $20 per share, a 4% increase from his most recent buy.

We track both varieties of insider trading, but insider purchases are particularly interesting. This is because insiders may sell for many reasons including diversification, but purchases are more likely to convey an insider’s feelings about the stock. Studies show that on average stocks bought by insiders outperform the market (read more about studies on insider trading).

Kronos Worldwide, Inc. is primarily a producer of titanium dioxide, which among other uses is an enhancer of coatings, plastics, and ceramics. Its recent rally reflects a perception that the company is set to recover from a poor 2012; the stock is actually down 8% from a year ago. The most recent data has 32% of the outstanding shares held short, however, so many market players- far from agreeing with Simmons that the stock will keep increasing in price- are in fact bearish. Looking at the company’s fundamentals, Kronos reported a 14% decrease in revenue in the third quarter of 2012 versus a year earlier and earnings were down almost 60%. At its current levels the stock trades at 15 times consensus earnings for 2013- that would be a fair price, with no particular attraction to the long or short side, but of course we wouldn’t take the precise numbers at face value. As a chemicals company, demand tends to be dependent on the broader economy and so the beta is 2.

How does Kronos compare to its peers?

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!